Technical Analysis for RHHBF - Roche Holding AG

Grade Last Price % Change Price Change
grade A 300.9 -2.07% -6.3500
RHHBF closed down 2.07 percent on Friday, December 13, 2019, on 61 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
See historical RHHBF trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Three Weeks Tight Range Contraction 0.00%
Inside Day Range Contraction 0.00%
New 52 Week Closing High Bullish -2.07%
180 Bullish Setup Bullish Swing Setup -2.07%
Expansion Breakout Bullish Swing Setup -2.07%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.07%
Reversal New Highs Setup Bullish Swing Setup -2.07%
New 52 Week High Strength -2.07%
Older signals for RHHBF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit roche.com
Health Pharmaceuticals Pharmaceutical Industry Life Sciences Diabetes Pharmaceutical Industry In China Infectious Diseases Chemotherapy Antibiotics Neuroscience Genentech Diabetes Management Hoffmann La Roche In Vitro Diagnostics World Health Organization Roche Personalised Healthcare Strategy Research Focused Healthcare Tissue Based Cancer

Is RHHBF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 307.25
52 Week Low 214.46
Average Volume 163
200-Day Moving Average 260.8736
50-Day Moving Average 285.5376
20-Day Moving Average 298.7571
10-Day Moving Average 302.8201
Average True Range 4.5273
ADX 28.0
+DI 51.7065
-DI 21.6501
Chandelier Exit (Long, 3 ATRs ) 293.6681
Chandelier Exit (Short, 3 ATRs ) 297.2646
Upper Bollinger Band 309.2861
Lower Bollinger Band 288.2281
Percent B (%b) 0.6
BandWidth 7.0485
MACD Line 5.1094
MACD Signal Line 5.5572
MACD Histogram -0.4478
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 308.7000
Resistance 3 (R3) 309.5667 307.8333 307.4000
Resistance 2 (R2) 307.8333 305.8469 307.4000 306.9663
Resistance 1 (R1) 304.3667 304.6197 303.5000 303.5000 306.5332
Pivot Point 302.6333 302.6333 302.2000 302.2000 302.6333
Support 1 (S1) 299.1667 300.6469 298.3000 298.3000 295.2668
Support 2 (S2) 297.4333 299.4197 297.0000 294.8337
Support 3 (S3) 293.9667 297.4333 294.4000
Support 4 (S4) 293.1000